HUMA vs. VALN, PROK, ALEC, KYTX, CABA, EXAI, ALLO, EVLV, VYGR, and CCCC
Should you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Valneva (VALN), ProKidney (PROK), Alector (ALEC), Kyverna Therapeutics (KYTX), Cabaletta Bio (CABA), Exscientia (EXAI), Allogene Therapeutics (ALLO), Evolv Technologies (EVLV), Voyager Therapeutics (VYGR), and C4 Therapeutics (CCCC).
Valneva (NASDAQ:VALN) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations, risk and community ranking.
In the previous week, Humacyte had 8 more articles in the media than Valneva. MarketBeat recorded 21 mentions for Humacyte and 13 mentions for Valneva. Humacyte's average media sentiment score of 0.41 beat Valneva's score of -0.05 indicating that Valneva is being referred to more favorably in the media.
Valneva has higher revenue and earnings than Humacyte. Valneva is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.
Valneva has a beta of 2.22, indicating that its stock price is 122% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.
11.4% of Valneva shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 23.1% of Humacyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valneva received 7 more outperform votes than Humacyte when rated by MarketBeat users. Likewise, 52.27% of users gave Valneva an outperform vote while only 50.00% of users gave Humacyte an outperform vote.
Humacyte has a net margin of 0.00% compared to Humacyte's net margin of -15.88%. Humacyte's return on equity of -14.56% beat Valneva's return on equity.
Valneva currently has a consensus price target of $21.67, suggesting a potential upside of 170.16%. Humacyte has a consensus price target of $8.00, suggesting a potential upside of 33.33%. Given Humacyte's stronger consensus rating and higher probable upside, equities analysts plainly believe Valneva is more favorable than Humacyte.
Summary
Valneva beats Humacyte on 11 of the 17 factors compared between the two stocks.
Get Humacyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Humacyte Competitors List
Related Companies and Tools
